findmyKOL

Alice Levine, MD

Basic profile

Icahn School of Medicine at Mount Sinai

ORCIDNPI
RegionNew York, NY · NortheastSpecialtyEndocrinology, Diabetes & MetabolismFocusEndocrinology/Metabolic
Last active 1994findmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH funding1990–1994Why? →

Alice Levine is an Endocrinology/Metabolic physician affiliated with Icahn School of Medicine at Mount Sinai. OpenAlex indexes 159 publications with 5,065 citations (h-index 36); ClinicalTrials.gov lists 2 registered studies matched to this name.

Overview

Scholarship

indexed output and impact (OpenAlex)
159publications

Distinct works indexed by OpenAlex, matched via ORCID.

5,065citations

Total citations across indexed works.

36h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
2clinical trials

Investigator role on registered studies.

View trials
3companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments
2NIH grants · 1990–1994

Federally funded research awards.

View funding

Clinical trials

Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.

Industry payments

3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

3 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Hormonal (systemic)

    53.5%
    l-Thyroxine50.3%
    Levothyroxine Sodium68%Synthroid32%
    Part D24 patients
    Mineralocorticoids3.2%
    Fludrocortisone Acetate100%
    Part D<11 patients
  • Sensory organs

    28.5%
    Corticosteroid28.5%
    Hydrocortisone90%Dexamethasone10%
    Part D<11 patients
  • Cardiovascular

    10.2%
    Aldosterone antagonist (MRA)10.2%
    Spironolactone53%Eplerenone47%
    Part D<11 patients
Where care is delivered (Part B)8.4% facility · 91.6% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

2 NIH research awards on record, funded 19901994 per NIH RePORTER. The latest:

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”